Premium
Pharmacokinetics of Oral Doses of Telmisartan and Nisoldipine, Given Alone and in Combination, in Patients With Essential Hypertension
Author(s) -
Bajcetic Milica,
Benndorf Ralf A.,
Appel Daniel,
Schwedhelm Edzard,
Schulze Friedrich,
Riekhof Daniel,
Maas Renke,
Böger Rainer H.
Publication year - 2007
Publication title -
the journal of clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.92
H-Index - 116
eISSN - 1552-4604
pISSN - 0091-2700
DOI - 10.1177/0091270006297225
Subject(s) - nisoldipine , telmisartan , concomitant , pharmacokinetics , medicine , tolerability , bioavailability , pharmacology , crossover study , regimen , bioequivalence , essential hypertension , placebo , blood pressure , nifedipine , adverse effect , alternative medicine , pathology , calcium
This randomized, single‐blind, parallel‐group study was performed to assess pharmacokinetic interactions potentially occurring during concomitant use of telmisartan and nisoldipine. Patients with essential hypertension (n = 37) were treated with once‐daily doses of telmisartan, nisoldipine, or their combination for 6 weeks. The regimen was started at low dose with an increase of dosage after 3 weeks of treatment. AUC ss (132%; P < .01) of telmisartan applied in doses of 80 mg was significantly higher after concomitant application with nisoldipine (10 mg), whereas CL/f ss (−54%; P < .05) and Vz/f ss (−72%; P < .05) were significantly lower. Regarding pharmacokinetic parameters of nisoldipine, significant differences between treatment groups were not detected. In conclusion, the results of this study strongly suggest that concomitant treatment with nisoldipine enhances telmisartan bioavailability in hypertensive individuals. Larger crossover trials will have to establish these observations and investigate whether interaction of both drugs affects telmisartan efficacy and tolerability in clinical use.